COMMUNIQUÉS West-GlobeNewswire

Essential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral Capsules
17/04/2024
Essential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral Capsules Reminyl® is an established CNS brand for the symptomatic treatment of mild to moderately severe dementia of the Alzheimer [...]
Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS
17/04/2024
Results from the Phase III study showed that subcutaneous (SC) injection was consistent with IV infusion and demonstrated near-complete suppression of relapse activity (97%) and MRI lesions (97.2%) through 48 weeks The [...]
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
17/04/2024
Continuous Kesimpta ® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis of the ALITHIOS open- [...]
Idorsia publishes a Financial Status required for an upcoming bondholder meeting
17/04/2024
Ad hoc announcement pursuant to Art. 53 LR Unaudited Financial Status as of March 31, 2024, required for an upcoming bondholder meeting, now available on the company website Bondholder meeting now planned for early May [...]
Press Release: New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis
17/04/2024
New 48-week frexalimab phase 2 data support potential for high sustained efficacy in multiple sclerosis Data support frexalimab as a potential first-in-class, high-efficacy, non-lymphocyte depleting treatment for [...]
Communiqué de presse : De nouveaux résultats de phase II à 48 semaines relatifs au frexalimab confortent le potentiel d'efficacité élevée et durable dans le traitement de la sclérose en plaques
17/04/2024
De nouveaux résultats de phase II à 48 semaines relatifs au frexalimab confortent le potentiel d'efficacité élevée et durable dans le traitement de la sclérose en plaques Les données montrent que le frexalimab a le [...]
TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering
17/04/2024
WALTHAM, Mass., April 17, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR [...]
Health Advocate Applauds Federal Budget 2024 in providing costing on a National Pharmacare Plan; a milestone in universal free access to contraceptives
17/04/2024
OTTAWA, April 16, 2024 (GLOBE NEWSWIRE) -- The Society of Obstetricians and Gynaecologists of Canada (SOGC) applauds the federal government’s announcement of $1.5 billion in funding over five years to support the launch [...]
Les professionnels de la santé des femmes applaudissent le budget fédéral 2024 incluant les coûts pour un Plan national d'assurance-médicaments; une étape importante vers un accès universel et gratuit à toutes les méthodes contraceptives
17/04/2024
OTTAWA, 16 avr. 2024 (GLOBE NEWSWIRE) -- La Société des obstétriciens et gynécologues du Canada (SOGC) applaudit l'annonce du gouvernement fédéral prévoyant 1,5 milliard de dollars sur cinq ans pour soutenir le [...]
Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
17/04/2024
SAN FRANCISCO, April 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the closing of its underwritten public offering of 11,916,667 shares of its common stock at a public offering [...]
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
16/04/2024
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in the U.S. on or after [...]
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
16/04/2024
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in the U.S. on or after [...]
Panbela Announces Transfer to OTCQB Market
16/04/2024
MINNEAPOLIS, April 16, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical [...]
Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024
16/04/2024
KANSAS CITY, Kan., April 16, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and [...]
INVO Reports Fourth Quarter and Full Year 2023 Financial Results
16/04/2024
SARASOTA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide [...]
CVRx to Report First Quarter 2024 Financial and Operating Results and Host Conference Call on April 30th, 2024
16/04/2024
MINNEAPOLIS, April 16, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative [...]
HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
16/04/2024
NEW YORK and VIENNA, Austria, April 16, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today [...]
Globus Medical Schedules First Quarter Earnings Release and Conference Call
16/04/2024
AUDUBON, Pa., April 16, 2024 (GLOBE NEWSWIRE) -- Globus Medical , Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the first quarter ended March 31, 2024 after the [...]
PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness
16/04/2024
Emergent shortages of the drug used to treat the most severe form of African sleeping sickness creates immediate need for direct access to the global drug market for affected nations As previously reported , PaxMedica [...]

Pages